Human beings are the most dominant species in the world’s history due to many reasons. However, if we sit down and unpack these reasons, we’ll realize few of them actually enjoy more influence than the others. Now, one among the former category is our ability to recognize opportunities. You see, time and time again, humans have discovered a way forward purely by spotting potential in a place where it’s hard to see anything at all. This ability would go on to reward us in such a manner that even the idea of constant progression won’t seem unfeasible. When the said dynamic is running the show, there will always be some natural by-products to emerge from it. While we’ll end up stumbling upon plenty here, none of them ever came close to matching technology. Technology’s meritorious rise to prominence has been an unbelievable journey by all means. Once again, turbo-charged by our ability of spotting opportunities, the creation has literally managed to achieve a strong presence across every major within our spectrum. Fortunately, though, the unprecedented work didn’t bring any complacency, as technology continues to deepen its impact on us through a diverse set of channels. In fact, looking at AbbVie’s recent acquisition, we can only expect this reality to grow further in near future.
AbbVie has officially acquired Syndesi Therapeutics for an upfront payment of $130 million. Considering AbbVie hasn’t done a ton around brain drugs, the move to acquire a company, which is popular for constructing a unique take on brain disorders, makes sense. Talk about Syndesi’s take on brain disorders, the company specializes around regulating synaptic transmission. By doing so it delivers a solution for all the disorders, which are caused on the back of disruption in synaptic activity, covering conditions like Alzheimer’s, dementia, and many more. Beyond that, Syndesi’s in-development drug candidate, SDI-118, is already slated to have a role across two disciplines, including age-related cognitive decline and adult remission from depression, with many others set to enter the picture soon.
“There is a major unmet need for new therapies that can help improve cognitive function in patients suffering from difficult-to-treat neurologic diseases. “With AbbVie’s acquisition of Syndesi, we aim to advance the research of a novel, first-in-class asset for the potential treatment of cognitive impairment associated with neuropsychiatric and neurodegenerative disorders,” said Tom Hudson, senior vice president, R&D, and chief scientific officer of AbbVie.
If everything goes well, the acquisition will significantly add to AbbVie’s breakout performance in neuroscience over the recent past. The company’s botox therapeutic accounted for nearly $2.45 billion in 2021 sales, so an expanded portfolio should only build upon those promising financial prospects. Apart from the upfront amount, the acquisition can also notably involve another $870 million in milestone payments.
